Clinical trials: Patients with Advanced Solid Tumors
Solid Tumor Malignancies, Malignant Mesothelioma (MM)
Study of TYK-01054 Capsules in Patients With Advanced Solid Tumors
This study is to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of the TEAD inhibitor TYK-01054 capsules in patients with locally advanced or metastatic advanced solid tumors
- Trial name
- NCT07282873
- Testing
- TYK-01054
- Where
- China
- Volunteers
- 219 people
- Sponsor
- TYK Medicines, Inc
Advanced Malignant Solid Neoplasm
Group Meaning-Centered Psychotherapy for the Improvement of Wellbeing in Caregivers of Patients With Serious Illness
This clinical trial assesses the acceptability and feasibility of a virtual group Meaning-Centered Psychotherapy for Cancer Caregivers (MCP-C) and its effect in improving the wellbeing of caregivers of patients with advanced…
- Trial name
- NCT06630351
- Testing
- Behavioral Counseling, Discussion, Health Promotion and Education
- Where
- 2 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Pancreatic Neoplasms, Solid Tumors
Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder
This study is open to adults with advanced cancer in the biliary tract, pancreas, lung, or bladder. This is a study for people for whom previous treatment was not successful or no treatment exists.
- Conditions
- Pancreatic Neoplasms, Solid Tumors, Biliary Tract Cancer, Lung Neoplasms
- Trial name
- NCT05512377
- Testing
- Brigimadlin
- Where
- 60 sites in United States, Australia and 14 more
- Volunteers
- 99 people
- Sponsor
- Boehringer Ingelheim
Unspecified Adult Solid Tumor, Protocol Specific
Eribulin Mesylate and Cisplatin in Treating Patients With Advanced Solid Tumors
This trial is studying the side effects and best dose of eribulin mesylate and cisplatin in treating patients with advanced solid tumors.Drugs used in chemotherapy, such as eribulin mesylate and cisplatin, work in different ways…
- Trial name
- NCT00415324
- Testing
- eribulin mesylate, cisplatin, laboratory biomarker analysis
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumors
Phase I Study of HBT-708 for Patients With Advanced Solid Tumors
The purpose of this study will be to evaluate the safety, tolerability, and inital efficacy of HBT-708 in subjects with advanced solid tumors.
- Trial name
- NCT06993870
- Testing
- HBT-708
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Advanced Solid Tumors
MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations
This is a multi- center, open-label, dose finding, Phase Ib study to be conducted in two stages: a dose escalation part to determine the maximum tolerated dose (MTD) safety and tolerability of concurrent administration of MEK162…
- Trial name
- NCT01352273
- Testing
- MEK162 + RAF265
- Where
- 8 sites in United States, Canada and 3 more
- Volunteers
- 69 people
- Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer
Head and Neck Cancer, Cervical Cancer
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous participant-derived engeneered T cells are engineered to express a T cell receptor that recognizes cancer-associated antigens…
- Conditions
- Head and Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma, Melanoma
- Trial name
- NCT05973487
- Testing
- TSC-204-A0201, TSC-204-C0702, TSC-200-A0201
- Where
- 21 sites in United States
- Volunteers
- 840 people
- Sponsor
- TScan Therapeutics, Inc.
Tumors
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of CUDC-101 in Patients With Advanced Solid Tumors
This is a phase I, open-label, dose-escalation study of CUDC-101 in patients with advanced and refractory solid tumors. CUDC-101 is a multi-targeted agent designed to inhibit epidermal growth factor receptor (EGFR), human…
- Trial name
- NCT00728793
- Testing
- CUDC-101
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Curis, Inc.
Solid Tumors
A Study of Tor Kinase Inhibitor in Advanced Tumors
The purpose of the study is to assess the safety, tolerability and pharmacokinetics of AZD8055 and determine the maximum tolerated dose to take into phase II trials.
- Trial name
- NCT00731263
- Testing
- AZD8055
- Where
- 4 sites in United States, France and 1 more
- Volunteers
- 64 people
- Sponsor
- AstraZeneca
Solid Tumors
Dose-Escalation Safety and Pharmacokinetic Study of Iso-Fludelone in Patients With Advanced Solid Tumors
Iso-fludelone is a type of chemotherapy drug called an epothilone. Epothilones are drugs that attach to proteins in your body called "tubulins". Tubulins help cells to grow, and are found in both normal and cancer cells.
- Trial name
- NCT01379287
- Testing
- Iso-Fludelone
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Solid Tumors, Lymphomas
Phase I and Pharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients With Solid Tumors or Lymphoma
This is a phase I and pharmacology study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients with Solid Tumors or Lymphoma. OBJECTIVES Primary: 1.
- Trial name
- NCT00947739
- Testing
- Camptothecin-20-O-Propionate Hydrate (CZ48)
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- New Mexico Cancer Research Alliance
Solid Tumor
A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.
This was a clinical study with an orally administered drug, BDTX-189 in participants with advanced solid tumors that had select mutations or alterations in human epidermal growth factor receptor 2 (HER2/ErbB2) genes or epidermal…
- Trial name
- MasterKey-01 (NCT04209465)
- Testing
- BDTX-189
- Where
- 38 sites in United States, Denmark and 2 more
- Volunteers
- 91 people
- Sponsor
- Black Diamond Therapeutics, Inc.
Solid Tumor, Solid Carcinoma
FORTRAS: A Study of MSK-TCR5 in People With Solid Tumor Cancers
The purpose of this study is to test the safety of MSK-TCR5 in participants with advance solid tumor cancer that has a KRAS, HRAS, or NRAS G12D mutation.
- Conditions
- Solid Tumor, Solid Carcinoma, Advanced Solid Tumor, Unresectable Solid Tumor
- Trial name
- NCT07638371
- Testing
- MSK-TCR5
- Where
- 7 sites in United States
- Volunteers
- 16 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Solid Tumor
Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors
This is a first-in-human (FIH), Phase 1a/1b, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of…
- Trial name
- NCT06598800
- Testing
- Drug: BG-T187, Other Therapeutic Agents
- Where
- 34 sites in United States, Australia and 2 more
- Volunteers
- 153 people
- Sponsor
- BeOne Medicines
Unspecified Adult Solid Tumor, Protocol Specific
Bryostatin 1 Plus Gemcitabine in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004144
- Testing
- bryostatin 1, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
HER2 or EGFR Expressing Advanced Solid Malignancies
MAD Refractory: Solid Tumor QD w/o Break
This is a continuous dosing Phase I Study of BMS-599626 in patients with HER2-expressing advanced solid malignancies.
- Trial name
- NCT00207012
- Testing
- BMS-599626
- Where
- 2 sites in France, Spain
- Volunteers
- 45 people
- Sponsor
- Bristol-Myers Squibb
Immune-related Adverse Events, Advanced Solid Tumor
Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)
The purpose of this study is to examine how effective rituximab or tocilizumab are in treating side effects for people who are receiving immunotherapy treatment requiring prolonged steroid use.
- Trial name
- NCT04375228
- Testing
- Rituximab, Tocilizumab
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- Columbia University
Advanced Solid Tumors
First in Human Trial of TAS266 in Patients With Advanced Solid Tumors
This study will assess safety, tolerability, maximum tolerated dose or recommended dose for expansion of TAS266 administered by IV infusion to patients with advanced solid tumors.
- Trial name
- NCT01529307
- Testing
- TAS266
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Novartis Pharmaceuticals
KRAS G12C
A Study of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations
Phase Ia: To evaluate the safety/tolerability of GFH925 in subjects with KRAS G12C-mutated advanced solid tumors; To estimate the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of GFH925.
- Trial name
- NCT05005234
- Testing
- GFH925
- Where
- China
- Volunteers
- 334 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Advanced HCC, Other Solid Tumors
KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors
This is a phase 1b/2, open label study to evaluate the safety, tolerability, pharmacokinetics and initial efficacy of KD6001 in combination with Tislelizumab ± Bevacizumab in patients with Advanced HCC and Other Solid Tumors.
- Trial name
- NCT05906524
- Testing
- KD6001, Tislelizumab, Bevacizumab
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Shanghai Kanda Biotechnology Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.